had had Bu-based transplant. The most common body area in AML was the head and neck (25%). Bone was less common in ALL/AML (<20%), than in CML (64%) and was typically associated with marrow relapse. Marrow relapsed with or after EMR in approximately 25% of ALL, 50% of AML, and 75% of CML cases. The most effective treatment was local plus systemic therapy, resulting in CR in most of 65 pts so treated. Of 28 pts given local therapy alone, only 6 survived 24 m, 4 of these had had testis relapse. Seven of 18 pts with AML/ALL treated with DLI+/-RT+/-chemo had CR of 2.5-60+ m. In total, 39 pts from case reports survived from 2 to 26+ yrs after EMR, only 2 of whom had CML. Combining and updating all available reported cases reveals that EMR post-BMT may occur: in any leukemia, and not more commonly in advanced disease; possibly more often in pts with abnormal karyotypes; and most commonly in soft tissue sites in AML/ALL, particularly breast and testis, and in bone in CML. Local and systemic therapy together has been most successful. Lengthy (2-26+yr) survival is demonstrated in at least 26% of reported cases and should encourage an aggressive approach when EMR occurs after transplant.
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T cells of recipient origin may consistently contribute to prompt recovery of Ag-specific T cell function of children given CBT D. Montagna, F. Locatelli, D Lisini, A. Moretta, S. Pagani, E. Montini, F. Bonetti, P. Grignani, A. Dehò, R. Maccario (Pavia, I) Cord blood transplantation (CBT) has been successfully used to rescue patients undergoing myeloablative therapy. As the number of Ag-specific mature T lymphocytes transferred with the graft, is significantly lower in CBT as compared with unmanipulated BMT recipients, some concern exist regarding the prompt recovery of donor-derived T cell immunity. We previously demonstrated that human cytomegalovirus (HCMV)-and candida albicans (CA)-specific CD4+ T lymphocytes of both donor and recipient origin may contribute to immune recovery after CBT. Aims of this study were to quantify the frequency of HCMV and CA-specific T cells in PBMC obtained from CBT recipients 2-3 and 12-15 months after transplant and to evaluate the contribution of recipient-and donorderived T cells to the development of immune response to these antigens. Frequency of HCMV-or CA-specific proliferating T cell precursors (PTCp) was evaluated in 9 children given CBT from either HLA-identical sibling (n=5) or from unrelated donor (n=4). Three out of 9 patients received a TBI-containing conditioning regimen. Sizeable or high frequencies of PTCp specific for HCMV (range: 1/1,900-1/25,000) or CA (range: 1/2,500-1/51,000) were found in 7 out of 9 patients both early and late after CBT. Interestingly, high frequency of HCMV-specific PTCp was documented in 5 patients in whom there was no evidence of viral reactivation. Analysis of Ag-specific T cell lines by PCR amplification of microsatellite DNA regions, demonstrated that in 4 patients 45-90% of responder lymphocytes were of recipient origin, while only a small contribution of recipient cells was found in the remaining patient. Similar ratio of donor/recipient cells was detected in CA-specific T cell lines obtained from PBMC of the same patients. Recipient cells were detected in the Ag-specific lines of patients who did not receive a TBI-containing conditioning regimen. In patients given TBI sizeable values of HCMV donorderived PTCp were found only in a patient in whom viral activation was observed. All together these findings demonstrate that: 1) TBI, as expected, impairs the possibility of recipient T cells to survive and expand after CBT, 2) Ag-specific T cells of recipient origin can play an important role in facing infectious complications in patients given CBT, without causing rejection, especially in the early post transplant period, when a primary immune response mediated by donor derived T cells is not fully developed.
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Thymic function after allogeneic stem cell transplantation in children M. Eyrich, D. Brügger, G. Wollny, B. Mascher, P. Bader, P. Lang, K. Schilbach, J. Greil, D. Niethammer, P.G. Schlegel (Tuebingen, Wuerzburg, D) Reconstitution of a mature T -cell compartment following allogeneic stem cell transplantation relies on the generation of naive T-cells via the thymus. However, thymic function may be adversely affected by the transplant procedure itself. In this study we assessed thymic function in 52 pediatric recipients (11 haploidentical, 19 unrelated, In conclusion, thymic function is severely affected by allogeneic stem cell transplantation, but, at least in children, recovers with time. Malignant disease is an unfavorable prognostic factor for thymic function in the first year post-transplant, probably due to heavier pretreatment. Further studies will identify factors that positively influence thymic function, e.g. higher numbers of transplanted stem cells or protection from radio-, chemotherapy induced thymic injury. An increased thymic function in the early post-transplant phase will accelerate T-cell reconstitution, thereby reducing transplant-related morbidity and mortality.
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Donor CMV serological status influences the outcome after unrelated donor stem cell transplantation; an EBMT Megafile analysis
Niederwieser, C. Cordonnier for the Infectious Diseases Working Party of the EBMT
Cytomegalovirus (CMV) has been one of the major causes of morbidity and mortality after allogeneic haematopoietic stem cell transplantation (HSCT). The importance of the recipient's serological status is paramount. However, the importance of the donor's serological status for outcome in CMV seropositive recipients is controversial. We analysed the influence of the donor's CMV serological status on outcome in a large cohort of patients. Data from 7018 CMV seropositive allogeneic SCT recipients reported to the European Group for Blood and Marrow Transplantation were included in the analysis. 5910 had undergone HLA-identical sibling SCT and 1108 unrelated donor SCT. Univariate and multivariate proportional hazards models were constructed for survival, event free survival, transplant related mortality, and relapse incidence. No influence of donor CMV status was found in HLA-identical sibling transplant recipients. Unrelated donor SCT recipients receiving grafts from CMV seropositive donors had improved 5-year survival (35% vs. 27%; HR=0.8), event free survival (30% vs. 22%; HR=0.8), and reduced transplant related mortality (49% vs. 62%; HR=0.7). There was no influence on the relapse incidence. The effects of donor CMV status remained present in multivariate analyses. The effect of donor CMV status were not the same in patients transplanted for different diseases. The effect of donor CMV status was pronounced in patients transplanted for CML and in patients with MDS and SAA, but was absent in patients transplanted for acute leukemia. In patients transplanted for chronic myelogenous leukaemia, T-cell depletion abrogated the beneficial effect of donor CMV status suggesting that the beneficial effect is mediated through transfer of donor immunity. We conclude that donor CMV status has a major impact on outcome of unrelated SCT. For a CMV seropositive patient, the data suggests that a CMV seropositive donor is preferable at least in patients with CML.
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Risk factors for CMV retinitis after allogeneic blood stem cell transplantation Preliminary results of an EBMT survey on CMV retinitis (CMVR) after blood stem cell transplantation (SCT) was reported at last years annual meeting. The study has been continued, and currently a total of 24 cases have been reported from 14 EBMT centres. Eighteen allogeneicly transplanted patients have been possible to include in a statistical analysis on risk factors for development of CMVR. One of these patients was HIV positive. The control group consisted of patients transplanted at the contributing centres during the study period, that had a follow up time of more than one month, which made a total of 2467 patients. The median time from transplantation to diagnosis of CMVR was 160 days (range 31-318) and the frequency was 0.73%. In the patients developing chronic GVHD, CMVR tended to be more common -2.08% (p=0.06). It tended to be even higher in patients developing extensive chronic GVHD -2.31% (p=0.053). The overall probability of developing CMVR was 1.07 ± 0.26%. In a multivariate analysis there was no significant increase in risk due to patient or donor age and sex, sex matching or HLA-matching. Chronic GVHD or extensive chronic GVHD did not increase the risk for CMVR in the multivariate setting, nor did acute GVHD. GVHD. The risk factors found or CMVR were: CMV-neg donor to CMV-pos patient, RR=4, p=0, 002) . Peripheral blood progenitor cells as graft, RR=3,65 (95% CI=1.37-9.73, p=0,01). Year of transplant later than 1996, RR=3,75 (95%CI=1.23-11.50,p=02). T cell depletion of the graft was no signioficant risk factor, but there was a tendency towards it, with RR=2,82 (95%CI=0. 98-8.12, p=0,054) . If the donor CMV-status was not considered, T-cell depletion also became a significant risk factor, with RR 4.04, 95% CI 1.37-11.9, p=0.011. In conclusion, the statistical analysis have confirmed that CMV retinitis has become a more common complication to allogeneic SCT. The patients with the largest risk for developing the complication, seems to be CMV positive patients with negative donors, transplanted with T -cell depleted peripheral blood progenitor cells. 
. Cordonnier on behalf of the Infectious Diseases Working Party of the EBMT
Epidemics are a continuous threat for any hospital, even more so for transplant programmes. The IDWP ran a survey so as to identify outbreaks of infection and their consequences for patient management in European stem cell transplant units between 1991-2001. A questionnaire was sent to the centres in June 2001 to collect data retrospectively. An outbreak of an infection was defined as an increase in the incidence of that infection above the expected incidence in the SCT unit with the proviso that there were no coincident changes in the case definition of infection, mode of surveillance, or the laboratory techniques used to identify the infection. Forty one centres returned the questionnaire. Twelve centres reported 19 outbreaks. The pathogens involved were respiratory viruses (4 centres, 6 outbreaks), bacteria, mainly Pseudomonas sp., and Vancomycin resistant enterococci (7 centres, 8 outbreaks), and fungi, Scedosporium (2 centres, 2 outbreaks), Paecilomyces lilacinus (1 centre, 1 outbreak) and Aspergillus sp. (2 centres, 1 outbreak). The centres had to close the ward or whole unit in 9 of these 19 outbreaks, for 2 to 12 weeks. Four centres stopped the transplant programme for the duration of the outbreak to prevent further transmission and to allow cleaning procedures, two additional centres maintained their transplant programme in other wards or hospitals. The deaths of fifty seven transplant patients were attributed to infectious agents involved in the outbreaks. Other non-transplanted patients were also affected. Outbreaks indeed can be a threat to patients and transplant units. Transplant units are encouraged to report outbreaks and to participate in surveillance programmes for infections, in order to either prevent or recognize the start of an outbreak, investigate to find the source, and take appropriate measures to protect patients. Awareness of epidemics should become a topic among transplant teams. In this way patient morbidity and mortality will be avoided, and the transplant programme will not be interrupted.
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Definitions of infectious diseases and complications after stem cell transplant
C. Cordonnier, D. Engelhard, P. Ljungman, A. Dekker, P. Donnelly, H. Einsele, E. Holler, H. Link, A. Locasciulli, R. Martino, F. Offner, P. Reusser, M. Rovira, A. Ullmann, K. Ward 
for the Infectious Diseases Working Party of the EBMT
In the past, some confusion and variability in reporting has been noted with significant differences in incidences of infection among centres which may not be accurate. The growing knowledge of infectious complications after stem cell transplant makes it important that investigators agree on common definitions in the reporting of data, to insure that series are comparable. The IDWP of the EBMT has elaborated a list of definitions for infectious complications after stem cell transplant from published guidelines whenever possible, or from the consensus emerging from the members of the IDWP when no satisfactory definition has previously been proposed in the literature. This has been done for two purposes: -to make the data given to the EBMT Registry, more precise and common to all the centres. This should improve data management, insure the quality of the data in the EBMT centres and facilitate prospective and retrospective studies through the registry.
-to provide official definitions for the Group, so that authors may refer to these definitions for studies or surveys, including those done outside the registry.
S54
The first version of these definitions is available on the web site of the EBMT (ebmt.org) at the IDWP section. The definitions are presented in two parts: -one for the different clinical entities which are usually observed. Most of these entities are intended for entering infectious complications in the EBMT data base.
-the second for definitions regarding specific pathogens: bacteria, fungi, viruses, others. This double entry should help the investigators and data managers to establish the relationship between the clinical presentation, and the role of a pathogen. Although these definitions are not fully exhaustive and will probably evolve in the future according to the progress of investigative procedures, the Infectious Diseases Working Party and the Registry Committee recommend the EBMT members use the present version of these definitions when filling the infectionrelated complication section in the MED B forms. Suggestions from the EBMT members will be welcome in order to improve the next version.
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H. Schrezenmeier, J. Passweg, R. Oneto, B. Bruno, R. Barge, A. Bekassy, N. Frickhofen, M. Führer, W. Hinterberger, J. Hows, E.T. Korthof, P. Ljungman, A. Locasciulli, P. Marin, J. Marsh, S. McCann, A. Raghavachar, G. Socie, A. Tichelli, N. Zoumbus, A. 
Bacigalupo on behalf of the EBMT Aplastic Anaemia Working Party
The EBMT Aplastic Anaemia registry contains data of 6086 treatments (as of October 2001). Diagnosis were acquired aplastic anaemia (AA) in 85.8%, Fanconi Anaemia in 9.7%, other constitutional anaemias in 1.2%, pure red cell aplasia in 1% and PNH in 2.3% of cases. In patients with acquired AA etiology was considered idiopathic in 83.3%, post-hepatitis in 8.6%, druginduced in 6.1%, and toxic in 1.2% of cases. Most patients with acquired AA reported to the registry received allogeneic stem cell transplantation (SCT)(n=2894; 57.2%) or immunosuppressive treatment (IS) (n=2153, 42.8%) with or without hematopoietic growth factors. 81.2% of the patients were grafted from an HLAidentical sibling donor, 2.4% from an identical twin, 3.0% from a matched family donor, 4.4% from a mismatched family donor, 7.3% from a matched unrelated donor and 1.7% from a mismatched unrelated donor. The proportion of SCT from alternative donors increased from 13.5% in the era before 1995 to 23.4% since 1995. Since 1994 the number of allogenic PBSCTS for AA is steadily increasing (33.3% and 34.4% of HLA-id. sib. SCTs in 1999 and 2000, resp) . However, careful evaluation of the impact of stem cell source on outcome after transplantation for AA is required. Probability of survival after both allogeneic SCT and IS increased substantially over time. Probability of survival at 5 years after HLA-id. sibl. transplant was 0. 39, 0.60, 0.63, 0.74 and 0.72 in the periods before 1981, 1981-1985, 1986-1990, 1991-1995 and since 1996. In the same time periods probability of 5 year survival after IS was 0. 47, 0.57, 0.65, 0.76 and 0.75 . Factors leading to improved survival include omission of radiation from conditioning regimens, improved GvHD prophylaxis, introduction of multimodal IS and improved supportive treatment. The role of growth factors as a n adjunct to IS for AA is still unclear. Despite the overall improvement in outcome, survival of patients grafted from alternative donors is still significantly lower compared to HLA-identical sib. SCT. Survival at 3 years in patients grafted since 1995 is 0.75 for HLA-identical sibling SCT and 0.65, 0.56 and 0.23 for patients grafted from matched related, matched unrelated and mismatched unrelated donors. Thus, new trials in the SCT field should focus on evaluation of new regimens for alternative donor transplantation. For patients not eligible for allogeneic SCT the role of growth factors and new immunosuppressive drugs should be evaluated.
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Fludarabine, cyclophosphamide and ATG for alternative donor transplants in aplastic anemia -A report of the SAA Working Party A. Bacigalupo, F. Locatelli, G. Socié, G. Dini, A. Pession, A. Locasciulli, A. Prete, H. Schrezenmeier (Genoa, Pavia, I; Paris, F; Bologna, Rome, I; Berlin, D) Fifteen patients with severe aplastic anemia underwent an alternative donor transplant following a conditioning regimen without radiation: patients received fludarabine 30 mg/m^2 + cyclophosphamide 300 mg/m^2x4 +antithymocyte globulin (Thymoglobulin) 3.75 mg/kg on days-5-4-3-2 before transplant. The etiology was idiopathic in 8 and constitutional in 7 (Fanconi) . The donor was an unrelated donor in 10 or a family member in 5 (1 was a phenotypic matched father, 3 were one antigen mismatched relatives and one was 3 antigens mismatched). The source of stem cells was unmanipulated bone marrow in 14, and CD34+ selected PB cells in one. Graft versus host disease prophylaxis consisted of cyclosporin 1 mg/kg from day -7 to day +20 and methotrexate 10 mg/m^2 on days +1, +3, +6,+11 after transplant. All patients engrafted with a median level of donor chimerism of 100% within day +100 and 100% beyond day +100. One patient showed graft failure and died after conventional transplant of GvHD. Thirteen patients (86%) had grade 0-I acute GvHD , one had grade II and one grade III GvHD. Five patients (33%) developed chronic GvHD. At a median follow up interval of 286 days (range 71-1334) 11/15 (73%) patients survive with graft function. Survival was 75% and 71% respectively in acquired and Fanconi anemia. This study confirms that an immunosuppressive conditioning regimen is sufficient to engraft young patients with aplastic anemia, using unmanipulated bone marrow and CyA+MTX as GvHD prophylaxis. N. Kröger, T. Zabelina, P. Guardiola, V. Runde, J. Sierra, A. van Biezen, D. Niederwieser, A. Zander, T. 
AML / MDS
de Witte for the Chronic Leukaemia Working Party
Chronic myelomonocytic leukaemia (CMML) is a rare hematological neoplastic disease, characterised by increased monocytic cells in the bone marrow and peripheral blood. Because of dysplastic features, CMML was classified as a subtype of myelodysplastic syndromes (MDS) by the FAB group in 1982. We report the results of 50 allogeneic transplantations performed between 12/1988 and 1/2000 in 43 European centers in 32 male and 25 female with CMML. The median age at transplant was 44 years (range 19-63), and the median time from diagnosis to transplant was 9 months (range 1-57). 18 patients had excess blasts ranging from 5% to 30% at time of transplantation. Cytogenetic data was available in 34 pts, showing abnormal karyotype in 13 cases (mainly monosomy 7). Donors were HLA identical siblings in 38 cases, HLA matched unrelated in 6 cases, HLA mismatched related in 5 cases, and HLA matched other related in one cases. Two graft failures were observed (4%). Neutrophil engraftment (>500/mm³) and platelet engraftment (>50000/mm³) was reached after a median of 17 days (range 11-50) and 29 days (range 11-268), respectively. 26% experienced acute GvHD grade II-IV, while 18% developed severe aGvHD
